Evidence map›Paper›PMID 41413369›Full record

ArticleInternational urology and nephrology2026

Prospective associations between the CKD-mineral bone disorder and metabolic acidosis.

Hulya Taskapan, Sara Mahdavi, Antonio Bellasi, Berkay Taskapan, Paul Tam, Tabo Sikaneta

Abstract read
In one paragraph

Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Hulya TaskapanKidney Life Sciences Institute, Toronto, Canada.
Sara MahdaviScarborough Health Network, Toronto, Canada.
Antonio BellasiDepartment of Nephrology, Ente Ospedaliere Cantonale, Lugano, Switzerland.
Berkay TaskapanKidney Life Sciences Institute, Toronto, Canada.
Paul TamKidney Life Sciences Institute, Toronto, Canada.
Tabo SikanetaKidney Life Sciences Institute, Toronto, Canada. tsikaneta@shn.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe common chronic kidney disease (CKD)-associated complications of mineral bone disorder (MBD) and metabolic acidosis share some biochemical features that physiologic studies suggest may be linked by the effects of progressive acidosis on bone and kidney. To explore this further, we examined prospective associations between key elements of the CKD-MBD and the subsequent appearance of subclinical and clinical metabolic acidosis in patients with stage 3/4 CKD.

methodsPost hoc analysis of 1993 CAN AIM TO PREVENT participants followed for 2.86 years per participant. Mixed-effects linear and logistic regression were used to evaluate prospective associations between phosphate, calcium, 25(OH)D, PTH, and FGF-23 with (1) declining plasma bicarbonate, (2) subclinical metabolic acidosis (bicarbonate 22-24 mmol/L), and (3) clinical metabolic acidosis (bicarbonate < 22 mmol/L).

resultsEach mmol/L increase in phosphate predicted a lower bicarbonate (- 1.29 mmol/L (95% CI - 1.61, - 0.98; p < 0.001)), and increased odds for subclinical (OR 1.92 (1.32, 2.79); p = 0.001) and clinical metabolic acidosis (OR 5.03 (3.16, 7.93); p < 0.001). Each mmol/L increase in calcium predicted a higher bicarbonate (2.70 mmol/L (2.11, 3.30; p < 0.001)), and decreased odds for subclinical (OR 0.23 (0.11, 0.46); p < 0.001) and clinical metabolic acidosis (OR 0.15 (0.06, 0.37); p < 0.001). Each unit increase in log-transformed 25(OH)D predicted a higher bicarbonate (0.38 mmol/L (0.23, 0.53); p < 0.001)), and decreased odds for subclinical (OR 0.67 (0.56, 0.80); p < 0.001) and clinical metabolic acidosis (OR 0.65 (0.50, 0.82); p < 0.001). Log-PTH exhibited a non-linear relationship with acidosis risk: moderate elevations were associated with reduced acidosis risk (OR 0.60 (0.40, 0.90); p = 0.013), while higher levels predicted an increased risk for subclinical (OR 1.42 (1.02, 1.98); p = 0.041) but not clinical metabolic acidosis (OR 1.44 (0.93, 2.24); p = 0.103). No significant associations were found between log-FGF-23 and acidosis risk (OR 1.02 (0.88, 1.19); p = 0.767).

conclusionKey elements of the CKD-MBD were independently and prospectively associated with the subsequent development of subclinical and clinical metabolic acidosis. Future studies could examine whether a causal relationship exists between progressive metabolic acidosis and the CKD-MBD.

Indexed as

AcidosisChronic Kidney Disease-Mineral and Bone DisorderRenal Insufficiency, ChronicAgedBicarbonatesCalciumFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsHumansMaleMiddle AgedParathyroid HormonePhosphatesProspective StudiesVitamin DBicarbonatesCalciumFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth FactorsParathyroid HormonePhosphatesVitamin DBone mineral disorder of CKDChronic kidney diseaseFGF-23HyperchloremiaHyperparathyroidismHyperphosphatemiaHypocalcemiaMetabolic acidosisSubclinical metabolic acidosisVitamin D deficiency

Identifiers

PMID41413369
PMCPMC13309459

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.